Retatrutide: What to Expect, Week-by-Week First Month

What Retatrutide Actually Is

Retatrutide (LY3437943) is a single peptide molecule that activates three distinct metabolic receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). That triple mechanism separates it from semaglutide (GLP-1R only) and tirzepatide (GIP/GLP-1R dual agonist). Jastreboff et al. Confirmed this receptor profile in their 2023 Phase 2 publication.

Why the Glucagon Receptor Matters

Adding glucagon receptor activity raises basal energy expenditure and increases hepatic fat oxidation. Glucagon stimulates thermogenesis in brown adipose tissue and accelerates lipolysis. Those effects complement the appetite suppression and insulin sensitization driven by GLP-1R and GIPR activation, which may explain why retatrutide's weight loss figures at 48 weeks exceeded those of tirzepatide at comparable timepoints.

Where Retatrutide Stands in 2025

As of mid-2025, retatrutide remains investigational. Eli Lilly has initiated the Phase 3 TRIUMPH trial program, but the FDA has not approved retatrutide for any indication. Patients accessing retatrutide outside a clinical trial are doing so through compounding pharmacies, which carry additional regulatory and quality-control considerations. The Phase 2 data published in the New England Journal of Medicine remain the primary evidence base.

The Phase 2 Trial: The Numbers You Need to Know

The Jastreboff et al. Phase 2 trial enrolled 338 adults with a body mass index of 30 or above, or 27 or above with at least one weight-related comorbidity, and no diabetes. Participants were randomized to placebo or one of five retatrutide dose groups (1 mg, 4 mg, 8 mg, 12 mg with a slow escalation schedule, or 12 mg with a faster escalation schedule) for 48 weeks. The full results appeared in the New England Journal of Medicine in June 2023.

Weight Loss Outcomes at 48 Weeks

• The 12 mg slow-escalation group achieved 24.2% mean body-weight loss (roughly 26 kg from a baseline near 108 kg).
• The 8 mg group achieved 17.3% mean body-weight loss.
• The 4 mg group achieved 8.7% mean body-weight loss.
• Placebo participants lost 2.1% mean body weight.

All active-dose groups showed statistically significant reductions versus placebo (P<0.001 for the 8 mg and 12 mg groups). These figures are reported in Table 2 of the Jastreboff NEJM publication.

Cardiometabolic Secondary Endpoints

Beyond weight, the 12 mg group reduced waist circumference by a mean of 23.2 cm at 48 weeks. Fasting insulin fell by approximately 47% and triglycerides by roughly 42% from baseline in the highest-dose group. Jastreboff et al. Reported these cardiometabolic findings alongside the primary weight outcomes. For context, the SELECT cardiovascular outcomes trial for semaglutide 2.4 mg showed 20% relative risk reduction in major adverse cardiovascular events, providing a benchmark against which retatrutide's Phase 3 cardiovascular data will eventually be compared. The SELECT trial protocol and design are publicly registered and described via ClinicalTrials.gov entries; the NEJM published SELECT results from Lincoff et al. In 2023.

The Month-1 Dose Escalation Schedule

In the Phase 2 protocol, all participants started at 2 mg once weekly for the first four weeks before escalating. This cautious opening is not arbitrary. GLP-1R and GIPR agonism slows gastric emptying from the first injection, which means nausea probability is highest early on, before the gut adapts. Starting low limits dropout from side effects.

The Standard Phase 2 Escalation Ladder

| Weeks | Dose | |-------|------| | 1 to 4 | 2 mg once weekly | | 5 to 8 | 4 mg once weekly | | 9 to 12 | 8 mg once weekly | | 13+ | 12 mg once weekly (target) |

Real-world compounding prescriptions often mirror this ladder, though individual prescribers may adjust timing based on tolerability. Patients who experience significant nausea or vomiting at any step should not escalate until symptoms are manageable for at least two consecutive weeks.

Week-by-Week: What to Expect in the First Month

The first 28 days on retatrutide are defined by one overriding reality: you are at the lowest dose (2 mg), and the drug has not yet reached its clinical efficacy plateau. Weight loss during this period is modest. The primary job of Month 1 is tolerability, not transformation.

Week 1: The First Injection and the Early Signal

Most patients self-inject retatrutide subcutaneously into the abdomen, thigh, or upper arm using a prefilled pen or a reconstituted vial. The injection itself is typically painless. Within 12 to 48 hours of the first injection, the majority of patients notice at least mild nausea, reduced appetite, or early satiety at meals.

In the Phase 2 trial, nausea was reported in 55.7% of patients in the 12 mg escalation groups, with the majority of events rated mild or moderate in severity. These adverse-event frequencies are detailed in the supplementary appendix of Jastreboff et al. At 2 mg, nausea rates are lower, but the signal is still present because even low-level GLP-1R activation slows gastric emptying measurably.

Practical actions for Week 1:

• Eat smaller portions at each meal, stopping before the point of fullness.
• Avoid high-fat, greasy foods for the first 72 hours post-injection.
• Stay well hydrated; nausea is often worse with mild dehydration.
• Inject at the same time each week (many patients prefer evening to sleep through the peak nausea window).

Week 2: Adaptation Begins

By the second injection, a significant subset of patients report that nausea is already less intense than it was after injection 1. This is consistent with receptor desensitization and gastric accommodation. Appetite suppression becomes more noticeable as the drug achieves a more consistent steady-state plasma concentration.

Patients may begin noticing that they feel full after eating roughly 30 to 40% less food than their typical portion. Spontaneous reduction in caloric intake without deliberate calorie counting is one of the more clinically useful early signals that the drug is working as intended. The glucagon receptor component may also contribute to a subtle increase in baseline energy, which some patients describe as feeling less fatigued after meals.

Early weight changes in Week 2 are typically 0.5 to 1.5 kg below baseline. This reflects a combination of reduced caloric intake, reduced glycogen-bound water (each gram of glycogen stores roughly 3 grams of water), and early fat mobilization.

Week 3: Side-Effect Peak and the Constipation Shift

Week 3 tends to be the most variable week in Month 1. Some patients experience a secondary uptick in gastrointestinal symptoms because the ongoing slowing of gastric motility begins to manifest lower in the GI tract as constipation rather than nausea. Others see Week 3 as a comfortable plateau where both side effects and appetite suppression have settled.

In the Phase 2 trial, constipation was reported in 23.8% of participants across active arms, and vomiting in 24.7% at higher doses. Jastreboff et al. Provided the full adverse event table in the NEJM supplementary data. At 2 mg in Week 3, these rates are lower, but the pattern still applies. Increasing dietary fiber and fluid intake reduces constipation risk substantially.

Patients who vomit more than twice in a single week, or who cannot tolerate liquids, should contact their prescriber before their next injection. Dose delay, not abandonment, is the typical clinical response to significant intolerance early in the escalation.

Week 4: Completing the Starting Dose Phase

By the end of Week 4, most patients have adapted reasonably well to 2 mg. Appetite suppression is consistent. The average patient has lost somewhere between 1 and 3 kg depending on dietary adherence, baseline metabolic rate, and activity level. That number will look modest against the 24.2% figure from the NEJM trial, but those outcomes accumulate over 48 weeks of escalating doses, not 4 weeks at the starting dose.

The clinical framework below summarizes what "on track" looks like at the end of Month 1, and when to flag concerns:

On track at Day 28:

• Nausea present but manageable (not requiring anti-emetics daily).
• Noticeable reduction in hunger between meals and smaller comfortable portions at meals.
• Weight down 1 to 3 kg from baseline.
• No injection-site reactions beyond transient redness.

Flag for prescriber review:

• Persistent vomiting preventing adequate oral intake.
• No appetite change whatsoever after two injections.
• Severe injection-site induration or nodule formation.
• Any new abdominal pain radiating to the back (requires ruling out pancreatitis; GLP-1 class signals for pancreatitis exist across the drug family, though causality remains debated in the literature).

Managing Side Effects in Month 1

Nausea: The Most Common Early Complaint

Nausea from retatrutide is mechanistically identical to nausea from semaglutide or tirzepatide: slowed gastric emptying increases gastric distension and activates vagal afferents projecting to the area postrema. The GLP-1R in the dorsal vagal complex is also directly activated. The CNS mechanisms of GLP-1-induced nausea are reviewed in a 2023 paper in Cell Metabolism.

Ondansetron 4 mg as needed is commonly prescribed alongside GLP-1-class drugs during the first few weeks, though data specific to retatrutide are not yet available. Eating slowly, chewing thoroughly, and avoiding carbonated beverages reduce meal-associated nausea in most patients.

Injection-Site Reactions

Subcutaneous injection of peptide drugs produces transient redness, mild swelling, or itching at the injection site in a minority of patients. Rotating injection sites with each dose reduces the risk. Lipoatrophy (fat-tissue loss under the skin) at the injection site is a rare but documented phenomenon with repeated subcutaneous peptide injections; it has been observed with insulin and is theoretically possible with GLP-1-class drugs.

The Muscle-Mass Question

One concern raised about deep caloric restriction with GLP-1-class drugs is lean mass preservation. The STEP-1 trial (N=1,961) for semaglutide 2.4 mg showed that approximately 40% of weight lost was lean mass when measured by DEXA. Ryan et al. Analyzed body composition data from STEP-1 and published findings in Obesity in 2023. Retatrutide's glucagon receptor activity theoretically increases fatty-acid oxidation preferentially, which may favor lean-mass preservation over pure GLP-1 agonism, but dedicated body-composition data from Phase 3 TRIUMPH trials are not yet published. Resistance training three times per week and protein intake at 1.6 g per kg of body weight per day are the current standard recommendations to protect lean mass during any GLP-1-class treatment.

How Retatrutide Compares to Tirzepatide and Semaglutide

Placing retatrutide in clinical context requires comparing its Phase 2 data against Phase 3 data for approved drugs, which is an imperfect comparison. Phase 2 trials typically enroll selected populations and may show inflated effect sizes.

| Drug | Mechanism | Peak Trial Weight Loss | Trial/Phase | |------|-----------|------------------------|-------------| | Semaglutide 2.4 mg | GLP-1R | 14.9% at 68 weeks | STEP-1 Phase 3 (N=1,961) | | Tirzepatide 15 mg | GIP/GLP-1R | 20.9% at 72 weeks | SURMOUNT-1 Phase 3 (N=2,539) | | Retatrutide 12 mg | GIP/GLP-1R/GCGR | 24.2% at 48 weeks | Phase 2 (N=338) |

STEP-1 data are published in Wilding et al., NEJM 2021. SURMOUNT-1 data are published in Jastreboff et al., NEJM 2022. Retatrutide Phase 2 data are from Jastreboff et al., NEJM 2023.

The 24.2% figure at 48 weeks is numerically remarkable. However, STEP-1 and SURMOUNT-1 were 68-week and 72-week trials respectively, and retatrutide's trajectory at 48 weeks in the Phase 2 had not yet plateaued. Phase 3 TRIUMPH data will determine whether those outcomes are reproducible at scale.

Who Should Not Start Retatrutide

Retatrutide shares contraindications with other GLP-1-class drugs and carries additional considerations from its glucagon receptor activity.

Established Contraindications From the GLP-1 Drug Class

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). GLP-1R agonists carry an FDA boxed warning for MTC risk based on rodent data; this warning extends to all drugs in the class. The FDA prescribing information for semaglutide documents this boxed warning and serves as a class reference.
• Active or recent pancreatitis. GLP-1-class drugs have a class-level signal for pancreatitis; prescribers should obtain baseline lipase in at-risk patients.
• Pregnancy or planned pregnancy within the treatment period.

Additional Considerations for Retatrutide Specifically

Glucagon receptor agonism raises hepatic glucose output. In patients with poorly controlled type 2 diabetes on sulfonylureas or insulin, this could theoretically increase hypoglycemia risk or complicate glycemic management. The Phase 2 trial excluded patients with diabetes, so this interaction has not been clinically characterized in a controlled setting. A 2022 review in Diabetes Care summarized glucagon's physiologic role and the implications of pharmacologic GCGR activation for glycemic management. Muller et al., Diabetes Care 2017 remains a key reference on the glucagon axis in metabolic disease.

Practical Checklist Before Starting Retatrutide

The following is based on standard pre-treatment workup for GLP-1-class drugs, adapted for retatrutide's triple-receptor profile.

Labs to obtain at baseline:

• Comprehensive metabolic panel (fasting glucose, LFTs, creatinine, electrolytes)
• Fasting lipid panel
• HbA1c
• Thyroid function (TSH)
• Serum lipase (baseline reference for pancreatitis monitoring)
• Body composition assessment (DEXA or InBody) if lean-mass tracking is a goal

Medication review:

• Oral medications with narrow therapeutic windows may have altered absorption due to slowed gastric emptying. Levothyroxine should be taken 60 minutes before injection or 4 hours after. Oral contraceptives may have reduced peak plasma concentrations; backup contraception for the first month of treatment is a reasonable precaution consistent with guidance applied to other GLP-1 drugs. The FDA guidance on drug interactions with GLP-1R agonists is available through the FDA drug label repository.

Patient education points:

• Retatrutide requires consistent weekly injection timing.
• Missing a dose by more than 4 days typically warrants skipping that dose and resuming the next scheduled injection rather than doubling up.
• Weight loss slows dramatically without adequate protein intake and progressive resistance training.

The TRIUMPH Phase 3 Program: What to Watch For

Eli Lilly's TRIUMPH trial program will determine whether retatrutide earns FDA approval. The program includes trials in obesity without diabetes, obesity with type 2 diabetes, and cardiovascular outcomes. Key metrics to watch in TRIUMPH publications:

1. Replication of the 24.2% weight loss figure in a larger, more diverse population.
2. Lean mass preservation data from DEXA sub-studies.
3. Cardiovascular event data to establish whether GCGR agonism is cardioprotective or neutral (glucagon has positive chronotropic effects that could theoretically raise heart rate similarly to GLP-1R agonists).
4. Long-term safety data on the thyroid C-cell signal beyond 48 weeks.
5. Effect on non-alcoholic steatohepatitis (NASH), where the glucagon receptor's hepatic fat-clearing mechanism may produce distinct benefits. A 2021 paper in the Journal of Hepatology examined GCGR agonism and hepatic steatosis. Valdecantos et al., J Hepatol 2021 provides relevant context on GCGR and liver fat.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends that all patients on anti-obesity medications engage in lifestyle intervention simultaneously, noting that pharmacotherapy without behavioral support consistently produces inferior long-term outcomes. The full guideline is available from the Endocrine Society at endocrine.org.